

# DECASAN®

Decamethoxine

**Composition of the drug:** active substance: decamethoxine; 1 ml of the solution contains 0.2 mg decamethoxin; auxiliary components: sodium chloride, water for injections.

**Pharmaceutical form.** Solution. Translucent colorless solution.

**Manufacturer name and location.** Yuria-Pharm Ltd. 10 M. Amosova Str., 03680 Kyiv, Ukraine.

**Pharmacotherapeutic group.** Antiseptic and disinfecting agents. ATC code D08A.

Decasan has antimicrobial and antifungal effects and concentrates on the cytoplasmic membrane (CPM) of a microbial cell and links with the membrane's phosphatide lipid groups, disrupting the penetrability of the microorganism's CPM. Decamethoxin has a pronounced bactericidal effect on staphylococci, streptococci, diphtheria and blue pus bacilli, and capsuliferous bacteria; a fungicidal effect on yeast, yeast-like fungi, agents of epidormophytosis, trichophytia, microsporia and erythrasma, certain mold fungi (aspergilli, penicilli); an antitenial effect on trichomonads and giardia lamblia; and an antiviral effect on viruses. The drug is highly active against antibiotic-resistant microorganisms. Creation of decamethoxin-resistant forms during prolonged therapy is slow and does not exceed the effective concentrations of the drug. Bacteriostatic (fungistatic) concentrations are similar to its bactericidal (fungicidal), viruocidal and antitenial concentrations. The sensitivity of antibiotic-resistant microorganisms to antibiotics is increased during the drug therapy. Absorption of the drug by mucous membranes, undamaged skin and wound surface is virtually absent.

**Indications.** Treatment of pustular bacterial and fungal skin diseases, microbial eczema, pyoinflammatory soft tissue lesions (abscesses, carbuncles, phlegmons, furuncles, festered wounds, whitlows); and dental diseases (stomatitis, acute necrotizing ulcerative gingivitis, dystrophic-inflammatory stage I and II paradontosis in the active phase).

Indicated for patients with pulmonary abscesses, bronchiectatic disease, cystic lung hypoplasia complicated by festering, chronic bronchitis in the active phase, chronic tonsillitis, quinsy, carriage of staphylococci and diphtheria bacteria, ulcerative colitis, and paraproctitis. In gynecological practice – for treatment of the vaginal mucous membrane candidosis, bacteriogenic inflammatory diseases of the genitalia, prenatal birth canal sanitation, and treatment of postpartum endometritis.

Hygienic disinfection of hand skin and rubber gloves during patient inspection, medical procedures and small-scale operative treatments, pre-sterilizing disinfection of medical instruments and diagnostic equipment made of metals, rubber, polymers and glass.

**Contraindications.** Individual hypersensitivity to the components of the drug.

**Precautions during administration.** Decamethoxine has no toxic effects in the concentrations used in Decasan®. Prolonged drug therapy causes no toxic reactions. Heating of the drug up to 38°C before administration increases its efficiency. In inflammation and skin irritation the drug is diluted in distilled water at the ratio of 1:1 or 1:2.

**Special administration precautions.** Administration during pregnancy or lactation. Precautions concerning administration during pregnancy or lactation are absent.

**Impact on the reaction time for driving or operation of machinery.**

Precautions concerning the impact on the reaction time in driving or operating machinery are absent.

**Administration in children.** No data on experience of administration in children are available.

**Administration and doses.** For pustular and fungal skin diseases and festering wounds, the solution is used as a wash or poultice. For treatment of proctitis and ulcerative colitis, 50-100 ml of warm solution is administered as enema, twice daily,

until all signs of acute inflammation are gone. In cases of chronic paraproctitis, fistulas are washed with Decasan® on a daily basis during 3-4 days. For bladder irrigation in adults, 500-600 ml of decamethoxin solution is used, diluted in purified water, 1 to 7 ratio (7 to 20 washes per treatment course). Lesions of the oral cavity mucous membranes are treated by applying 25-50 ml of the solution during 10-15 minutes, or by gargling (100-150 ml). For dystrophic-inflammatory stage I and II paradontosis in the active phase, gums pockets are irrigated with warm solution (50-70 ml), or solution is applied to the gums until inflammation symptoms cease. Patients with candidiasis of the oral cavity mucous membranes and acute necrotizing ulcerative gingivitis are prescribed mouth gargling (100-150 ml) four times daily, during 5-10 days. For treatment of tonsillar candidiasis and chronic tonsillitis, tonsillar lacunae washing is prescribed (50-75 ml per wash). Sanitation of carriers of staphylococci and diphtheria bacteria is done by throat gargling, lacunae washing, and nasopharynx and tonsil irrigation. Lacunae washing is done every other day, 3-5 times daily. In cases of pulmonary abscesses, bronchiectatic disease, cystic lung hypoplasia complicated by festering, and chronic bronchitis in the active phase, intrabronchial administration of Decasan® is performed: via microtracheostomy – 25-50 ml 1-2 times daily; via a transnasal catheter – 5-10 ml once daily; via ultrasound inhalation – 5-10 ml 1-2 times daily; via tracheobronchial tree lavage – 100 ml. Treatment course duration is 2-4 weeks. For treatment of microbial, fungal and trichomonad diseases of the vaginal mucous membranes, Decasan® is applied by sprinkling (50-100 ml of the solution warmed to 38°C, 3 times daily). The same method is used for prenatal birth canal sanitation, in a single procedure. For treatment of postpartum endometritis, the uterine cavity is washed with 150-200 ml of warm solution, twice daily. Disinfection of hand skin and rubber gloves is done by applying 5-10 ml of the drug on a previously washed surface and distributing it evenly throughout the surface to be disinfected, during 5 minutes. Cleaned medical instruments, bite-boards, tubes and equipment is disinfected by being immersed into the solution for 30 minutes.

**Overdosing.** Due to the lack of absorption, overdosing is not observed.

**Side effects.** In isolated cases, individual hypersensitivity possible.

In such patients, skin rash may appear after the use of the drug, burning sensation, dryness, itching after administration of the drug and other local allergic reactions after intrabronchial administration, a sensation of heat behind the breastbone is possible, alleviated 20-30 minutes after the end of the procedure.

**Interaction with other drugs and other forms of interaction.**

Pharmaceutical: decamethoxin is a cationic surface-active agent, so it is incompatible with soap and other anionic compounds. Pharmacodynamic: decamethoxin increases the sensitivity of antibiotic-resistant microorganisms to antibiotics.

**Shelf life.** 3 years.

**Storage conditions.** Keep out of reach of children. Store in a dark place at temperatures not exceeding 25°C. Don't freeze.

**Packaging.**

50 ml, 100 ml, 200 ml and 400 ml glass bottles, 50 ml, 100 ml, 250 ml, 500 ml, 1000 ml, 2000 ml, 3000 ml and 5000 ml polymer containers (bags).

**Sales list.** Over-the-counter.



# DECASAN®

Decamethoxine



## The first of a kind inhalable antiseptic

 YURiA-PHARM

[www.uf.ua/int](http://www.uf.ua/int)


Yuriya-Pharm Ltd.

10 M. Amosova Str., Kyiv 03680, Ukraine

tel./fax: +380 (44) 275-01-08; 275-92-42

 YURiA-PHARM

[www.uf.ua/int](http://www.uf.ua/int)



## DECASAN® – the first of a kind inhalable antiseptic

### DECASAN® via inhalations is used at:



Diseases of the upper respiratory tract:	Diseases of the lower respiratory tract:
<ul style="list-style-type: none"> <li>acute and chronic rhinitis</li> <li>pharyngitis</li> <li>tonsillitis</li> <li>tracheitis</li> <li>laryngitis</li> </ul>	<ul style="list-style-type: none"> <li>acute and chronic bronchitis</li> <li>pneumonia</li> <li>cystic fibrosis</li> <li>obstructive pulmonary disease</li> </ul>

### DECASAN®: spectrum of activity against bacteria and fungi

Culture	S. aureus	S. epidermidis	S. pyogenes	E. faecalis	E. coli M-17	E. coli ATCC25922	P. rettgeri	P. morganii	P. aeruginosa	P. putida	P. fluorescens	A. baumannii
MIC*	0.78	0.78	0.78	0.39	1.56	1.56	50.0	50.0	25.0	25.0	1.56	25.0
MBC**	3.12	6.25	3.10	1.56	6.25	6.25	50.0	50.0	50.0	50.0	3.10	25.0

\* MIC - The minimal inhibitory concentration

\*\* MBC - The minimal bactericidal concentration




## DECASAN®: effective treatment of influenza

Viruses	Time of Decasan exposure	Virucidal activity
Influenza A(H1N1)	5 minutes	+++
Influenza A(H3N2)	5 minutes	+++
Vesicular stomatitis virus (strain Indiana)	5 minutes	+++

### DECASAN® is active ONLY AGAINST MICROBIAL cells and does not affect human cells.

Decamethoxine is a surface-active agent (SAA), exerting its action via disruption of cellular wall integrity. The cellular wall of microorganisms consists of short lipid chains subject to rapid decomposition with DECASAN®.



### The mechanism of action of DECASAN®:

- Increased permeability of the bacterial cell and its destruction
- Inactivation of exotoxin
- Inhibition of protein synthesis and its division

### The main characteristics of DECASAN®:

- Bactericidal, fungicidal, virucidal, sporicidal activity
- Anti-inflammatory effect
- Desensitizing effect
- Potentiates the effect of antibiotics
- Does not cause burns of the mucous membrane
- Promotes elimination of microbial plasmids
- Antispasmodic effect